Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transformed Lymphoma / DLBCL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07714421
What this trial is testing

Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients

Who this might be right for
Diffuse Large B-Cell LymphomaGrade 3b Follicular LymphomaHigh Grade B-Cell Lymphoma+2 more
Jonsson Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT07473167
What this trial is testing

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Who this might be right for
Relapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)+3 more
TICAROS Co., Ltd. 98
Testing effectiveness (Phase 2)UnknownNCT04796857
What this trial is testing

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Who this might be right for
Non-GCB/ABC Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 30
Early research (Phase 1)Study completedNCT02924402
What this trial is testing

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Who this might be right for
B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Xencor, Inc. 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT05583149
What this trial is testing

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Who this might be right for
Refractory Aggressive B-cell LymphomasRefractory B-Cell Non-Hodgkin LymphomaAggressive B-cell NHL+10 more
Patrick C. Johnson, MD 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT04889716
What this trial is testing

CAR-T Followed by Bispecific Antibodies

Who this might be right for
Large B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma
Abramson Cancer Center at Penn Medicine 23
Early research (Phase 1)Looking for participantsNCT07424833
What this trial is testing

APG-3288 in Relapsed/Refractory Blood Cancers

Who this might be right for
Relapsed/Refractory Hematological MalignanciesRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLLRelapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)+4 more
Ascentage Pharma Group Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07735533
What this trial is testing

UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

Who this might be right for
Lymphoma, B CellLymphoma Non-HodgkinHigh Grade B Cell Lymphoma+4 more
Umoja Biopharma 274
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Ended earlyNCT05328102
What this trial is testing

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large-cell B-cell Lymphoma
Xencor, Inc. 3
Testing effectiveness (Phase 2)Ended earlyNCT02572453
What this trial is testing

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell Lymphoma+5 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Study completedNCT01897571
What this trial is testing

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Who this might be right for
B-cell Lymphomas (Phase 1)Advanced Solid Tumors (Phase 1)Diffuse Large B-cell Lymphoma (Phase 2)+3 more
Epizyme, Inc. 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Testing effectiveness (Phase 2)UnknownNCT04476459
What this trial is testing

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 33
Testing effectiveness (Phase 2)UnknownNCT02628405
What this trial is testing

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma+5 more
Academic and Community Cancer Research United 30
Not applicableNot Yet RecruitingNCT07476378
What this trial is testing

Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies

Who this might be right for
Lymphoma, Large B-Cell, Diffuse (DLBCL)Lymphoma, FollicularLymphoma, Mantle-Cell+3 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 69
Testing effectiveness (Phase 2)Ended earlyNCT02378038
What this trial is testing

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Who this might be right for
Richter's Transformation
Sierra Oncology LLC - a GSK company 5
Testing effectiveness (Phase 2)Study completedNCT02348216
What this trial is testing

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B-Cell LymphomaTransformed Follicular Lymphoma (TFL)+2 more
Kite, A Gilead Company 307
Early research (Phase 1)WithdrawnNCT05228249
What this trial is testing

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+7 more
Fred Hutchinson Cancer Center
Early research (Phase 1)Ended earlyNCT05828589
What this trial is testing

BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Chronic Lymphocytic Leukemia+11 more
BeOne Medicines 51
Next Page
180